MONTRÉAL, June 03, 2024 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. ("Triple Hair" or the "Company"), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has closed a $4 million financing with a group of investors. The main investors are Prevail Partners, New Brunswick Innovation Fund and the Québec government, through its Impulsion PME program (biopharmaceutical component), managed by Investissement Québec. This financing is a first step in the evolution of Triple Hair's capital structure leading to the execution of Phase III clinical trials in several countries for the Company's flagship prescription product, Therapy-07. The trials will measure the efficacy of Therapy-07 on hair regrowth to treat androgenic alopecia. "This is an important milestone for Triple Hair, both in terms of securing funding and the recognition of the potential value of Therapy-07 by reputable financial institutions," said Jean-Philippe Gravel, President and CEO of Triple Hair. "These funds will notably enable us to prepare the Phase III clinical trials planned for Therapy-07. We have Health Canada's approval to begin our Phase III clinical trials, and awaiting approvals from other jurisdictions, notably the US and Europe. As soon as we receive these approvals, we will proceed to finalize our capital structure and begin clinical trials in several countries." "Triple Hair's ingenious approach to alopecia is inspiring, and promises to improve ...